Sapreme Therapeutics has shared new preclinical data from its lead Duchenne muscular dystrophy (DMD) programme, SPM-2551, at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), taking place in Denver, Colorado, US. 

SPM-2551 is intended to restore dystrophin to more than 15% of normal levels – a level expected to be clinically meaningful on patients with DMD – while using lower doses and less frequent dosing than current therapies.  

It does this by combining a muscle-targeting transferrin receptor 1 (TfR1)-targeting antibody, an exon-skipping antisense oligonucleotide (ASO), and Sapreme’s endosomal escape enhancer, known as SPT. 

Larger molecules, like oligonucleotide-based RNA therapeutics, face a significant delivery bottleneck. Even after successful cellular uptake, most of the oligonucleotide payload will typically remain trapped within endosomes – effectively sealing the drug off from the rest of the cell and preventing it from reaching its intracellular target. With up to 99% of the intended RNA payload remaining in endosomes, this significantly limits therapeutic potential.  

Sapreme says SPT overcomes this challenge, allowing substantially more of the RNA therapeutic to escape endosomes and act on the target as intended. 

“The data presented at OTS highlight the tremendous potential of Sapreme’s SPT platform to overcome intracellular delivery, one of the biggest challenges in RNA therapeutics,” said Marco Timmers, Chief Executive Officer of Sapreme Therapeutics. “These findings demonstrate that by combining targeted delivery with efficient endosomal escape, Sapreme can drive robust and durable pharmacological activity at exceptionally low tissue exposures. In terms of DMD, a truly devastating muscle-wasting disease, we believe these data are unprecedented in the field, showing superior efficacy after only a single, low dose, beyond any of the existing data of marketed therapies and programs currently in development.” 

Restored dystrophin to very high levels 

The presentation highlighted results from multiple preclinical species, including non-human primates, demonstrating robust target engagement and durable pharmacological activity despite requiring dramatically lower tissue exposure than unconjugated oligonucleotides or conventional antibody-oligonucleotide conjugates. 

In a humanised DMD model, SPM-2551 demonstrated 5-10-fold higher exon skipping than both naked and targeted comparator oligonucleotides at an order of magnitude lower ASO dose, leading to greater dystrophin restoration.  

Following the lowest single doses of 1 and 3mg/kg, SPM-2551 restored dystrophin to more than 35% and 55% of wild-type levels after 56 days, respectively, demonstrating dose-dependent and sustained activity. 

Professor Annemieke Aartsma-Rus, Professor Human Genetics at Leiden University, said: “Four RNA therapies have been approved for different DMD subgroups, but there is definitely room for improvement. In our DMD mouse models, Sapreme’s lead candidate SPM-2551 restored dystrophin to very high levels after only a single low dose, substantially exceeding what we observed in comparators without targeting or without enhanced endosomal escape.”